SORRENTO THERAPEUTICS INC - COMMON STOCK (SRNE)

Historical Holders from Q1 2014 to Q3 2025

Type / Class: Equity / COMMON STOCK
Symbol: SRNE on OTC
Price per share: $0.003300
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares as of 30 Sep 2025: 5,351
Total reported value: $20
% of total 13F portfolios: 0%
Share change: +350
Value change: +$1
Avg buy value change: 0%
Number of holders: 2

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

As of 30 Sep 2025, SORRENTO THERAPEUTICS INC - COMMON STOCK (SRNE) has 2 institutional shareholders filing 13F forms. They hold 5,351 shares. .

Institutional Holders of SORRENTO THERAPEUTICS INC - COMMON STOCK (SRNE) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (% of par)	Investors
2025 Q3	5,351	$20	+$1			0.33%	2
2025 Q2	5,001	$6				0.12%	1
2025 Q1	5,001	$4	-$62			0.08%	1
2024 Q4	144,701	$66	+$32			0.05%	4
2024 Q3	79,051	$287	-$225			0.4%	3
2024 Q2	86,801	$826				0.95%	3
2024 Q1	88,001	$704	-$3,025			0.8%	4
2023 Q4	109,638	$13,894	+$5,108			12.35%	6
2023 Q3	66,437	$6,423	-$2,013			9.4%	6
2023 Q2	74,097	$26,064	-$1,579,450			35.68%	8
2023 Q1	4,389,675	$1,580,580	-$173,161,604	$0	$0	36%	31
2022 Q4	204,003,018	$180,750,718	+$27,197,640	$2,134,909	$1,386,710	88.6%	212
2022 Q3	165,762,637	$260,256,913	+$17,763,512	$1,950,000	$2,734,000	157%	209
2022 Q2	153,297,183	$308,144,111	+$48,179,957	$2,772,000	$3,258,000	200.92%	203
2022 Q1	129,336,776	$301,512,034	+$75,599,318	$3,282,000	$6,149,000	232.99%	214
2021 Q4	91,645,723	$426,183,587	+$26,211,105	$9,270,000	$18,793,000	465%	209
2021 Q3	86,096,158	$657,561,692	+$65,745,110	$16,294,000	$30,324,000	763%	207
2021 Q2	77,149,796	$747,565,086	+$1,414,796	$22,122,000	$43,329,000	969%	198
2021 Q1	77,548,810	$641,223,132	-$13,783,269	$20,395,000	$29,565,000	826.98%	217
2020 Q4	79,202,133	$540,694,339	+$44,885,220	$31,177,250	$32,306,000	682.5%	202
2020 Q3	72,163,622	$804,895,770	+$125,419,268	$38,490,000	$86,690,000	1,115%	200
2020 Q2	61,410,387	$385,629,239	+$174,057,936	$14,526,000	$18,473,000	628%	173
2020 Q1	33,811,041	$62,254,702	+$2,508,579	$592,000	$746,000	184.01%	86
2019 Q4	31,701,710	$107,169,899	+$25,585,968	$1,143,000	$426,000	338.01%	83
2019 Q3	24,399,262	$52,204,793	-$10,629,147	$419,000	$226,000	214%	80
2019 Q2	28,113,883	$75,058,304	+$15,035,647	$521,000	$367,000	267%	77
2019 Q1	22,833,498	$108,453,864	-$37,461,189	$1,200,000	$729,000	475%	79
2018 Q4	31,275,547	$75,056,104	-$13,013,577	$180,000	$140,000	239.99%	73
2018 Q3	33,487,424	$147,301,505	+$18,214,854	$1,193,000	$209,000	440%	95
2018 Q2	29,083,598	$209,401,309	+$46,994,951	$3,372,000	$2,380,000	719.99%	90
2018 Q1	23,454,567	$120,808,725	+$62,046,855	$1,256,000	$169,000	514.99%	68
2017 Q4	10,151,815	$38,589,600	+$1,955,327	$4,000	$4,000	380%	46
2017 Q3	9,853,493	$16,752,000	-$4,957,108	$6,000	$9,000	170%	35
2017 Q2	12,450,704	$24,906,000	-$4,035,502	$9,000	$13,000	200%	44
2017 Q1	13,286,327	$52,483,948	+$1,086,275	$23,000	$17,000	395%	64
2016 Q4	14,507,257	$71,080,983	+$197,981	$16,000	$31,000	489.98%	67
2016 Q3	13,023,723	$100,801,046	+$1,434,486	$181,000	$422,000	774%	60
2016 Q2	12,861,202	$72,020,801	-$50,844	$1,000	$65,000	560%	62
2016 Q1	12,885,767	$69,317,000	-$3,468,733	$88,000	$16,000	538.01%	68
2015 Q4	13,106,546	$114,169,970	-$14,578,469	$238,000	$180,000	871.01%	82
2015 Q3	14,793,662	$124,115,199	+$16,878,346	$2,694,000	$3,022,000	839%	88
2015 Q2	11,650,681	$205,285,244	+$52,201,852	$548,000	$1,170,000	1,762.01%	74
2015 Q1	8,926,085	$103,140,000	+$18,874,990	$1,937,000	$1,373,000	1,155.97%	55
2014 Q4	7,317,782	$73,712,000	+$174,503			1,006.97%	35
2014 Q3	6,512,433	$29,478,000	+$713,473			452.01%	30
2014 Q2	7,641,687	$51,546,000	+$13,237,819			674.89%	35
2014 Q1	3,732,491	$47,850,000	+$13,674,719			1,282%	28